Soeren Cold

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer

Vernon Harvey, Henning T. Mouridsen, Erik Jakobsen et al. · Journal of Clinical Oncology · 2006 · 160 citations

Medicine, Oncology, Pharmacology +16

Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group

Anders Husted Madsen, Anni Ravnsbæk Jensen, Peer Christiansen et al. · Acta Oncologica · 2008 · 16 citations · Full text

Medicine, Biostatistics, Oncology +17

Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

Volkmar Müller, Andrew Wardley, Elisavet Paplomata et al. · European Journal of Cancer · 2021 · 13 citations · Full text

Medicine, Oncology, Pharmacology +17